Trial Profile
Adjuvant post-surgery therapy with imatinib in gastrointestinal stromal tumor patients with intermediate or high risk:a single-centre, open-label, non-controlled study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Apr 2016
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Sponsors Novartis
- 20 Nov 2009 New trial record